Cannabis shows promise in treating schizophrenia and tourette syndrome

n Nigeria Cannabis is associated with a lot of bad bad omen but that is if you are still caught up in outdated facts.

Cannabis in recent years has become more widely accepted and that is due to the numbers of studies telling us of the many good side to the herb.

And one of such good side is its ability due to a certain compound it possesses (cannabis-derived chemical cannabidiol (CBD) ) to help contain the cognitive effects in schizophrenic patients.

The study review on the compound that took place at the University of Wollongong, was conducted by Dr. Katrina Green, Professor Nadia Solowij, and Wollongong PhD candidate Ashleigh Osborne.

According to Dr. Katrina Green:

“From this review, we found that CBD will not improve learning and memory in healthy brains, but may improve aspects of learning and memory in illnesses associated with cognitive impairment, including Alzheimer’s disease, as well as neurological and neuro-inflammatory disorders,”

“We found that CBD was able to restore recognition and working memory, as well as social behavior, to normal levels,” Osborne said in a release. “These findings are interesting because they suggest that CBD may be able to treat some of the symptoms of schizophrenia that are seemingly resistant to existing medications. In addition, CBD treatment did not alter body weight or food intake, which are common side effects of antipsychotic drug treatment.”

Osborne explaining to ABC News Australia, “This is really important because current antipsychotic drugs don’t address the cognitive deficits, which approximately 80% of patients with schizophrenia experience.”

“This is the first study to prove Cannabidiol can be used to treat symptoms of schizophrenia that aren’t addressed by current medications,” Osborne told ABC News. “These findings are really promising but further research is needed to see if these findings translate to people suffering from schizophrenia.”

She added, “Ultimately, we hope that these findings lead to new improved medications.




Medical Marijuana Maybe Coming Soon To German Pharmacies – German legislators and politicians prepared a draft proposal this month that seeks, among other things, to create a new government agency that will regulate and oversee the medical marijuana industry in Germany. If the proposal is accepted by Parliament, the reforms that will follow will be dramatic and rapid.

A New Medical Marijuana System in Germany

The draft bill and proposal come as welcome relief for Germany’s growing population of medical marijuana patients, who must currently seek an exemption license from the government in order to acquire and use cannabis.

Under the proposed new laws, any doctor will be able to prescribe cannabis products to patients for a wide variety of more than 60 disorders and conditions, including intractable pain, mental disorders, major illnesses as well as specific symptomatic treatment.

The New German Medical Marijuana Laws At-a-Glance:

Program will be managed by a new government organization under the auspices of the Federal Institute for Drugs and Medical Devices
Patients will be limited to a maximum of 100 grams per month
Any doctor can prescribe cannabis products
Any pharmacy can dispense cannabis products
Medicines approved under the bill include raw flower, extracts and pharmaceuticals
Insurance companies must reimburse patients for cannabis medicines
Patients must take part in research in order to qualify for insurance reimbursement

What it means for the German Government

The German government likely have a new source of revenue if the bill passes, depending on how taxation is implemented. This revenue could be substantial considering that all aspects of the medical cannabis industry – from cultivation to transportation to distribution – will be under State control. This means that in theory there will be new funds for additional social programs or initiatives.

As members of the European Union; they will be obligated to perform mandatory reporting and notifications to the EU. Germany is bound by law to disclose to the EU that it will begin regulating and thereby making available to its citizens – and by proxy the citizens of its neighbors – marijuana. This requirement forces any country that passes “favorable” legislation that reduces or eliminates restrictions on narcotics to report this change to the EU for consideration.

Is it safer to drive high than drunk? Efforts to curtail marijuana-impaired driving collide with attitudes, medicinal use

A recent Colorado Department of Transportation survey found that 72 percent of Colorado cannabis consumers thought it was safer to drive under the influence of marijuana than under the influence of alcohol

By Alicia Wallace, The Cannabist Staff

Promoting cannabis as a safer alternative to alcohol was a tenet of the marijuana legalization movements in Colorado and other states.

Early data indicate that attitude continues when people get behind the wheel.

A recent Colorado Department of Transportation survey found that 72 percent of Colorado cannabis consumers thought it was safer to drive under the influence of marijuana than under the influence of alcohol.

That same survey also found that more than half of the 92 cannabis-using respondents drove within two hours of consuming marijuana. An equal percentage believed they could safely drive under the influence of marijuana.

Terpineol: The Terpene Smells like Lilac and Kills Tumors

Terpineol is the terpene that is present in more than 150 plants including marijuana. It also can be found in pine trees, lilac, and rosemary. The smell and the taste of terpineol, the terpene, are a bit elusive. The reason is that terpineol doesn’t occur alone in cannabis and is often accompanied by alpha-pinene.

Terpineol is a beautiful fragrant oil that smells like lilac with lapsang souchong tea undertones.It is often utilized in cosmetics and soap production for its breathtaking smell.

More than that, terpineol has incredible health benefits for cancer patients: the study published 8 years ago in Anticancer Research revealed that terpineol has excellent antitumor properties. As most terpenes, this one can be used for pain management. The study published in Chemico-Biological Interactions detrermined it in the course of a lab experiment.

Some studies admit that terpineol has excellent anti-inflammatory and antioxidant properties.

Strains With Terpineol

OG Kush cannabis strain

is one of the most common strains with terpineol. It’s easy to find this one in a dispensary. Besides, OG Kush cannabis strain is a rather potent and energizing hybrid with an astonishing citrus smell.




White Widow

has this elusive lilac smell that is blocked by more powerful citrus and earth aromas. White Widow cannabis strain is my favorite balanced hybrid that delivers this pleasant zen-like buzz. Just love it! Now when I know about terpineol in it, I will smoke it even more.


Girl Scout Cookies1

is another popular strain with terpineol. Consumers love this strain for its instant euphoric effect. The minute you inhale Girl Scout Cookiescannabis strain’s smoke you feel at peace with the world.


New York Firm Partners with MS Researcher for Phase 2 FDA-Approved Study

MMJ Bioscience has partnered with the executive director of the New York State Multiple Sclerosis Consortium, Dr. Bianca Weinstock-Guttman, on a Food and Drug Administration-approved study testing the potential therapeutic applications of medical cannabis for multiple sclerosis patients.

Weinstock-Guttman also serves as a Professor of Neurology at the State University of New York at Buffalo. She will serve as the principal investigator for MMJ Bioscience, an MMJ International Holdings affiliate.

Tom Ryan, MMJ Bioscience COO, indicated the partnership marks the initiation of their Phase 2 clinical trial for an Orphan Drug Designation from the FDA. Orphan drug designation is given to medicines that are found an effective “treatment, diagnosis or prevention” for conditions that affect fewer than 200,000 people.

“MMJ BioScience’s discovery of a novel cannabinoid pharmacology through our network of world leading scientists, our intellectual property portfolio, proprietary formulations, contract processing, and regulatory expertise uniquely position us to develop and manufacture plant-derived cannabinoid formulations at sufficient quality and uniformity according to the FDA regulatory requirements for pharmaceutical development,” he said in a press release, adding that successful Phase 2 trials could lead to an FDA fast-track designation.

The National Multiple Sclerosis Society supports the use of medical cannabis by patients and has called for more in-depth research on its use.

Pot Was Flying Off the Shelves in Uruguay. Then U.S. Banks Weighed In.

U.S. Marijuana Party Kentucky

Pot Was Flying Off the Shelves in Uruguay. Then U.S. Banks Weighed In.


A line outside a pharmacy selling legal marijuana last month in Montevideo, Uruguay. Credit Matilde Campodonico/Associated Press

The pharmacies selling pot were doing a brisk business.

After Uruguay became the first country in the world to fully legalize marijuana sales for recreational use last month, some of the pharmacies struggled to keep up with the demand.

Then came the stern letters from American banks.

The letters immediately sent officials in Uruguay scrambling to make sense of the Patriot Act and other American laws that could doom an essential part of their country’s new marijuana market.

American banks, including Bank of America, said that they would stop doing business with banks in Uruguay that provide services for those state-controlled sales.

Afraid of losing access to the American banking system, Uruguayan banks warned…

View original post 1.154 altre parole

Canada can be a world leader in medical cannabis

There are millions of people worldwide with chronic diseases and other medical conditions whose lives could be improved with better access to medical cannabis. Meanwhile, for the past decade and a half, Canada has built the most sophisticated medical cannabis framework in the world. These circumstances present an exceptional opportunity for trade leadership on the international stage.

Last year, the amount spent on cannabis worldwide — including medical cannabis — was US$150 billion. By comparison, Canada’s crude oil exports totalled C$49.8 billion in 2016. The federal government must proactively make medical cannabis exports part of its innovation agenda. With the right approach, the industry has the potential to be a significant contributor to Canada’s biotechnology and life sciences sectors.

We should leverage the success of Canada’s domestic medical cannabis model to address the gap in access to quality products worldwide. Thanks to the Access to Cannabis for Medical Purposes Regulations (ACMPR) and their predecessor regulations, Canada already has a growing network of experienced, responsible licensed producers committed to meeting and exceeding Health Canada’s high safety and security standards from seed to sale. More than 167,000 Canadians have come to rely on the quality of domestically produced products to ease the symptoms of conditions like post-traumatic stress disorder, epilepsy, cancer, and chronic pain — an increase of 123 per cent since April 2016.

Tilray serves tens of thousands of patients domestically. We also receive orders from governments, researchers, hospitals and pharmaceutical distributors around the world seeking pharmaceutical-grade medical cannabis products. In December 2016, Tilray became the first medical cannabis producer in North America to have a certificate of Good Manufacturing Practices (GMP) compliance published in the European Union’s GMP database. GMP certification is the most rigorous standard that manufacturers of medical products must meet in their production processes and enables our company to expand our international distribution. In 2016, Tilray became the first company to legally export medical cannabis products from North America to Australia and the European Union. Earlier this year, we made our first export to Latin America.

Under the current terms of the ACMPR — which are designed to prioritize domestic production and supply — the ability of licensed producers to meet global demand is still limited. Producers need fewer hurdles and more certainty so we can serve patients in need in nascent markets. Canada’s medical cannabis framework must be updated to better facilitate the ability of licensed producers to supply products to these markets for medical treatment, research and clinical trials. The federal government should work expeditiously to encourage, not curtail, their efforts in this field.

In February, when the European Parliament voted to approve the Canada-European Union trade agreement (CETA), Canada gained access to the world’s second-largest market: over 500 million consumers in 28 countries generating C$20 trillion annually in economic activity. Germany, with a population of 80 million, is a party to that agreement. This year, the country legalized medical cannabis, with full coverage for any patient authorized by a physician. Yet it is years away from a domestic supply chain and is looking to Canadian producers to fill that void. The same is true in Croatia, Ireland, Mexico and the many other countries that have medical cannabis coverage but lack a network of domestic producers and the safe, secure supply Canadians have come to depend on.

When Sir Frederick Banting discovered insulin nearly a century ago, Canadians did not turn inward, unwilling to share a medical breakthrough with patients in other countries and continents. Rather, through partnership with successive governments, strategic investments and a commitment to the open exchange of knowledge, health practitioners, researchers and industry set an agenda for quality patient care that has led to better health outcomes for millions of people with diabetes around the world. The same could now be true of Canada’s network of medical cannabis producers.

Canada has a chance to lead the world — it’s time to seize it.

To effectively seize this opportunity, the federal government should take the following three steps:

  • Mandate Health Canada to address existing limitations under the ACMPR, including production and expansion limitations, so that licensed producers with export capabilities can more readily provide products to growing international markets
  • Convene an expert roundtable of licensed producers, researchers and market analysts to develop a global export strategy specific to medical cannabis and to Canada as a leading biotech exporter of safe, high-quality medical cannabis products
  • Begin including representatives of the medical cannabis industry on future trade missions, particularly in areas such as the European Union, Latin America and the Asia-Pacific region

Prime Minister Trudeau has been clear that his government’s mandate is to build an innovation agenda that will create jobs and drive long-term economic growth. Supplying safe, high-quality medical cannabis products to international markets will do both. This sector of the economy employs thousands of Canadians in a diverse range of well-paying jobs, from horticulturalists to researchers to growers; these businesses have the potential to revitalize communities, bring in additional tax revenue for governments and sow the seeds of innovation in the Canadian economy.

The global public perception of cannabis is rapidly changing. The federal government has boldly kept pace with this change with its plan to legalize adult-use cannabis. This forward-looking approach should apply to medical cannabis, too. Canada has a chance to lead the world — it’s time to seize it.

How booming Israeli weed industry is changing American pot

Standing on the rear balcony of a gray factory building off the side of a highway, Tamir Gedo shields his eyes from the blazing sun. He points to the 23 acres of agricultural fields spread out before him. ‘We’ll be able to produce more cannabis here than the entire state of Colorado,’ he says. Minutes later, walking past the 8,000 square-foot storage room, he adds, ‘We can store enough in this warehouse to supply medical marijuana for the whole United States.’

Sorgente: How booming Israeli weed industry is changing American pot

Attenzione: la comprensione del Sistema Endocannabinoide potrebbe cambiare la tua vita!


Il sistema endocannabinoide, che prende il nome dalla pianta che ha portato alla sua scoperta, è il più importante sistema fisiologico coinvolto nella creazione e nel mantenimento della salute umana.

Come medico, sono naturalmente prudente rispetto a qualsiasi medicina che si prefigga di curare tutti.

Panacee, rimedi come l’olio di serpente e le costose mode del momento spesso vanno e vengono, con grandi rivendicazioni, ma con scarse prove scientifiche o cliniche per sostenerne l’efficacia.

Mentre esploro il potenziale terapeutico della cannabis, tuttavia, non trovo mancanza di prove.

Infatti, vi è un’enorme quantità di ricerche scientifiche sul potenziale terapeutico della cannabis, più prove di quanto si possa trovare su alcune delle terapie più utilizzate dalla medicina convenzionale.

Dustin Sulak, DO
Maine Integrative Healthcare



continua a leggere: